Stem cell transplant offers potentially curative therapy in pediatric patients with monogenic inflammatory bowel disease

A collaborative team of researchers from Children’s Hospital of Philadelphia (CHOP) found that hematopoietic stem cell transplantation (HSCT) is a highly effective method for treating patients with monogenic inflammatory bowel disease (IBD), a more severe form of the illness usually affecting younger patients. More than 90% of patients achieved sustained medication-free remission.